Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Jul

Today In Oncology

Opening Session Panel Discussion

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Long-Term Follow-up of Postoperative Chemoradiotherapy With 3-Weekly vs Weekly Cisplatin in Head and Neck Cancer

Advanced Gastric or GEJ Cancer First-Line Disitamab Vedotin, Tislelizumab, and S-1

In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types

Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma

Oral Cancer Novel Diagnostic Test Demonstrates High Accuracy